NCT04701502View on ClinicalTrials.gov

Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions
Covid19Respiratory DiseaseImmune SystemImmunomodulatorAntisepticSupportive Care
Interventions
DIETARY_SUPPLEMENT

Viusid

"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"

DIETARY_SUPPLEMENT

Asbrip

"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"

DRUG

Standard Care

Standard care for COVID-19

Trial Locations (2)

4000

MBAL, Sv. Mina, Plovdiv

4004

MTB Plovdiv, Plovdiv

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT04701502 - Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19 | Biotech Hunter | Biotech Hunter